Teresa Macarulla

21.3k total citations · 3 hit papers
315 papers, 8.7k citations indexed

About

Teresa Macarulla is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Teresa Macarulla has authored 315 papers receiving a total of 8.7k indexed citations (citations by other indexed papers that have themselves been cited), including 268 papers in Oncology, 101 papers in Pulmonary and Respiratory Medicine and 93 papers in Cancer Research. Recurrent topics in Teresa Macarulla's work include Pancreatic and Hepatic Oncology Research (157 papers), Cancer Genomics and Diagnostics (84 papers) and Colorectal Cancer Treatments and Studies (82 papers). Teresa Macarulla is often cited by papers focused on Pancreatic and Hepatic Oncology Research (157 papers), Cancer Genomics and Diagnostics (84 papers) and Colorectal Cancer Treatments and Studies (82 papers). Teresa Macarulla collaborates with scholars based in Spain, United States and Germany. Teresa Macarulla's co-authors include Josep Tabernero, Eric Van Cutsem, Michele Reni, Eileen M. O’Reilly, Do‐Youn Oh, Pascal Hammel, Francisco Javier Ramos, Talia Golan, Giampaolo Tortora and Daniel Hochhauser and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Teresa Macarulla

296 papers receiving 8.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer

2019 1.5k citations Talia Golan, Pascal Hammel et al. New England Journal of Medicine profile →
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

2012 986 citations Eric Van Cutsem, Josep Tabernero et al. Journal of Clinical Oncology profile →
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial

2023 185 citations Zev A. Wainberg, Davide Melisi et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Teresa Macarulla Spain	42	6.4k	2.9k	2.3k	2.2k	1.4k	315	8.7k
J. Randolph Hecht United States	32	7.1k 1.1×	2.5k 0.8×	2.5k 1.1×	2.7k 1.2×	1.2k 0.8×	121	9.2k
Marcia S. Brose United States	44	4.5k 0.7×	3.6k 1.2×	1.4k 0.6×	2.1k 0.9×	1.1k 0.8×	187	11.5k
Laura D. Wood United States	46	5.2k 0.8×	3.1k 1.1×	2.9k 1.3×	1.6k 0.7×	2.1k 1.5×	155	8.6k
Wells A. Messersmith United States	52	5.3k 0.8×	4.3k 1.5×	1.7k 0.7×	1.8k 0.8×	673 0.5×	298	9.5k
Sae‐Won Han South Korea	50	5.0k 0.8×	2.7k 0.9×	1.7k 0.7×	2.9k 1.3×	1.0k 0.7×	274	8.1k
Helen X. Chen United States	37	4.1k 0.6×	3.9k 1.3×	2.0k 0.8×	2.6k 1.2×	696 0.5×	84	8.9k
Robert Radinsky United States	45	6.3k 1.0×	4.5k 1.6×	2.2k 1.0×	2.5k 1.1×	863 0.6×	127	10.4k
Élena Elez Spain	38	4.5k 0.7×	1.7k 0.6×	1.2k 0.5×	1.4k 0.6×	951 0.7×	212	6.1k
Napoleone Ferrara United States	12	5.7k 0.9×	3.6k 1.3×	1.8k 0.8×	2.4k 1.1×	1.2k 0.8×	16	9.6k
Nilofer S. Azad United States	41	3.8k 0.6×	2.3k 0.8×	1.3k 0.5×	1.4k 0.6×	1.1k 0.8×	205	6.3k

Countries citing papers authored by Teresa Macarulla

Since Specialization

Citations

This map shows the geographic impact of Teresa Macarulla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Teresa Macarulla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Teresa Macarulla more than expected).

Fields of papers citing papers by Teresa Macarulla

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Teresa Macarulla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Teresa Macarulla. The network helps show where Teresa Macarulla may publish in the future.

Co-authorship network of co-authors of Teresa Macarulla

This figure shows the co-authorship network connecting the top 25 collaborators of Teresa Macarulla. A scholar is included among the top collaborators of Teresa Macarulla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Teresa Macarulla. Teresa Macarulla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Felip, Enriqueta, et al.. (2025). Off-label use of olaparib in uncommon tumor locations in patients with impaired homologous recombination genes. Farmacia Hospitalaria. 49(5). 286–290.

Castet, Florian, et al.. (2025). Genomic profiling unlocks new treatment opportunities for ampullary carcinoma. ESMO Open. 10(5). 104480–104480.

Pant, Shubham, Jia Fan, Do‐Youn Oh, et al.. (2024). Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study.. Journal of Clinical Oncology. 42(16_suppl). 4091–4091. 11 indexed citations

Hussein, Maen, Gazala Khan, Sreenivasa R Chandana, et al.. (2024). NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated overall survival analysis with 29-month follow-up of NAPOLI 3.. Journal of Clinical Oncology. 42(16_suppl). 4136–4136. 2 indexed citations

He, Aiwu Ruth, Do‐Youn Oh, Teresa Macarulla, et al.. (2024). TOURMALINE: A phase 3b study of durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer.. Journal of Clinical Oncology. 42(16_suppl). TPS4188–TPS4188. 1 indexed citations

Visa, Laura, Elena Vázquez, Jaime Feliú, et al.. (2024). Update on the management of older patients with pancreatic adenocarcinoma: a perspective from medical oncology. Clinical & Translational Oncology. 26(7). 1570–1583. 3 indexed citations

Vergote, Ignace, Teresa Macarulla, Fred R. Hirsch, Carsten Hagemann, & David S. Miller. (2023). Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment. Cancers. 15(3). 636–636. 12 indexed citations

Vidal, Laura, Elizabeth Pando, L. Blanco, et al.. (2023). Liquid biopsy after resection of pancreatic adenocarcinoma and its relation to oncological outcomes. Systematic review and meta-analysis. Cancer Treatment Reviews. 120. 102604–102604. 8 indexed citations

Schram, Alison M., Kōichi Goto, Dongwook Kim, et al.. (2023). 1315MO Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC). Annals of Oncology. 34. S756–S757. 10 indexed citations

10.

Chiaravalli, Marta, Anthony Turpin, Florian Castet, et al.. (2023). Clinical and genomic characterization of pancreatic ductal adenocarcinoma patients with lung oligometastasis. SHILAP Revista de lepidopterología. 2. 100011–100011.

11.

Castet, Florian, Vı́ctor Navarro, Daniel Acosta, et al.. (2023). Clinical and genomic characterisation of early-onset pancreatic cancer. European Journal of Cancer. 194. 113338–113338. 11 indexed citations

12.

Hidalgo, Manuel, Rocio García‐Carbonero, Kian‐Huat Lim, et al.. (2022). A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas. Cancer Research Communications. 2(11). 1326–1333. 5 indexed citations

13.

Mirallas, Oriol, et al.. (2022). Advances in the systemic treatment of therapeutic approaches in biliary tract cancer. ESMO Open. 7(3). 100503–100503. 14 indexed citations

14.

Feliú, Jaime, Teresa Macarulla, Bartomeu Massutí, et al.. (2021). Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study. Cancer Chemotherapy and Pharmacology. 87(4). 543–553. 12 indexed citations

15.

Muro, Kei, Taylor Salinardi, Arvind R. Singh, & Teresa Macarulla. (2020). Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data. Cancers. 12(4). 844–844. 15 indexed citations

16.

Golan, Talia, Pascal Hammel, Michele Reni, et al.. (2019). Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer. New England Journal of Medicine. 381(4). 317–327. 1468 indexed citations breakdown →

17.

Hammel, P., Hedy L. Kindler, Michele Reni, et al.. (2019). Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. Annals of Oncology. 30(12). 1959–1968. 33 indexed citations

18.

Κάτσιλα, Θεοδώρα, Josep Gregori, Teresa Macarulla, et al.. (2014). Circulating pEGFR Is a Candidate Response Biomarker of Cetuximab Therapy in Colorectal Cancer. Clinical Cancer Research. 20(24). 6346–6356. 22 indexed citations

19.

Cervantes, Andrés, Élena Elez, Desamparados Roda, et al.. (2012). Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 18(17). 4764–4774. 119 indexed citations

20.

Cutsem, Eric Van, Josep Tabernero, Radek Lakomý, et al.. (2012). Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen. Journal of Clinical Oncology. 30(28). 3499–3506. 986 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact